Journal of Surgery Concepts & Practice >

2026 , Vol. 31 >Issue 01: 88 - 94

DOI: https://doi.org/10.16139/j.1007-9610.2026.01.15

Review

Controversy and collaboration of multi-disciplinary team in surgical treatment of secondary hyperparathyroidism

  • PAN Jiahao ,
  • LIN Sen ,
  • YANG Peng ,
  • WANG Qiang ,
  • CUI Xinhua ,
  • ZHANG Wei
Expand
  • 1 Department of Thyroid, Breast and Hernia Surgery, Changzheng Hospital, Shanghai 200003, China
    2 Department of General Surgery, Rongjun Hospital, Zhejiang Jiaxing 314051, China

Received date: 2025-05-04

  Online published: 2026-04-21

Fold

Abstract

The multi‑disciplinary team (MDT) care centered on parathyroidectomy (PTX) has gradually become the main treatment model for secondary hyperparathyroidism (SHPT). However, different departments such as surgery, nephrology, laboratory medicine, radiology, and endocrinology have varying understandings and treatment strategies for SHPT. This article, from a surgical perspective, reviewed the controversies and collaborations in MDT during the diagnosis and treatment of SHPT, including disputes with nephrology over the timing of surgery and treatment goals, collaboration with radiology for preoperative localization, collaboration with laboratory medicine for intraoperative monitoring of parathyroid hormone, collaboration with intensive care units, endocrinology, and cardiology in the management of complications such as electrolyte disorders, bone hunger syndrome, and cardiovascular events during the perioperative period, as well as disputes with the metabolic department regarding the evaluation of postoperative bone metabolism changes. This provided a reference for the clinical promotion of MDT diagnosis and treatment of SHPT.

Key words： Secondary hyperparathyroidism (SHPT); Parathyroidectomy (PTX); Parathyroid hormone (PTH); Multi‑disciplinary team (MDT)

Cite this article

PAN Jiahao , LIN Sen , YANG Peng , WANG Qiang , CUI Xinhua , ZHANG Wei . Controversy and collaboration of multi-disciplinary team in surgical treatment of secondary hyperparathyroidism[J]. Journal of Surgery Concepts & Practice, 2026 , 31(01) : 88 -94 . DOI: 10.16139/j.1007-9610.2026.01.15

References

[1] WANG L, XU X, ZHANG M, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance[J]. JAMA Intern Med, 2023183(4):298-310.
[2] WANG Y, LIU J, FANG Y, et al. Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease[J]. Front Endocrinol (Lausanne), 2024, 15:1400891.
[3] KETTELER M, BLOCK G A, EVENEPOEL P, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters[J]. Kidney Int, 2017, 92(1):26-36.
[4] RAMOS L, CORTES D, REIS L, et al. Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism[J]. J Bras Nefrol, 2024, 46(2):e20230024.
[5] CHEN L, WANG K, YU S, et al. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis[J]. Ren Fail, 2016, 38(7):1050-1058.
[6] EL-HUSSEINI A, WANG K, EDON A A, et al. Parathyroidectomy-a last resort for hyperparathyroidism in dialysis patients[J]. Semin Dial, 2017, 30(5):385-389.
[7] BURTON J O, GOLDSMITH D J, RUDDOCK N, et al. Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD[J]. BMC Nephrol, 2018, 19(1):240.
[8] KIM W W, RHEE Y, KIM B S, et al. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism[J]. Endocr J, 2019, 66(10):881-889.
[9] 胡国凤, 张晔, 何芸, 等. 彩超与99 mTc-MIBI SPECT/CT融合显像在继发性甲状旁腺功能亢进术前定位中的应用[J]. 局解手术学杂志, 2022, 31(11):994-999.
  HU G F, ZHANG Y, HE Y, et al. Application of color Doppler ultrasound and 99 mTc-MIBI SPECT/CT fusion imaging in preoperative localization of secondary hyperparathyroidism[J]. J Region Anat Oper Surg, 2022, 31(11):994-999.
[10] ZHANG R, ZHANG Z, HUANG P, et al. Diagnostic performance of ultrasonography, dual-phase (99m)Tc-MIBI scintigraphy, early and delayed (99m)Tc-MIBI SPECT/CT in preoperative parathyroid gland localization in se-condary hyperparathyroidism[J]. BMC Med Imaging, 2020, 20(1):91.
[11] 贺青卿, 田文. 慢性肾脏病继发甲状旁腺功能亢进外科临床实践中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(8):841-848.
  HE Q Q, TIAN W. Chinese expert consensus on surgical practice of hyperthyroidism in patients with chronic kidney disease(2021 edition)[J]. Chin J Pract Surg, 2021, 41(8):841-848.
[12] CHEN Y H, CHEN H T, LEE M C, et al. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound[J]. Ann Nucl Med, 2020, 34(8):527-537.
[13] DREAM S, KUO L E, KUO J H, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of secondary and tertiary renal hyperparathyroidism[J]. Ann Surg, 2022, 276(3):e141-e176.
[14] HIRAMITSU T, TOMINAGA Y, OKADA M, et al. A retrospective study of the impact of intraoperative intact parathyroid hormone monitoring during total parathyroidectomy for secondary hyperparathyroidism: stard study[J]. Medicine (Baltimore), 2015, 94(29):e1213.
[15] ZHANG L, XING C, SHEN C, et al. Diagnostic accuracy study of intraoperative and perioperative serum intact PTH level for successful parathyroidectomy in 501 secondary hyperparathyroidism patients[J]. Sci Rep, 2016, 6:26841.
[16] EL-HUSSEINI A, WANG K, EDON A, et al. Value of intraoperative parathyroid hormone assay during parathyroidectomy in dialysis and renal transplant patients with secondary and tertiary hyperparathyroidism[J]. Nephron, 2018, 138(2):119-128.
[17] WETMORE J B, LIU J, DO T P, et al. Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy[J]. Nephrol Dial Transplant, 2016, 31(1):103-111.
[18] SCHLOSSER K, BARTSCH D K, DIENER M K, et al. Total parathyroidectomy with routine thymectomy and autotransplantation versus total parathyroidectomy alone for secondary hyperparathyroidism: results of a nonconfirmatory multicenter prospective randomized controlled pilot trial[J]. Ann Surg, 2016, 264(5):745-753.
[19] CAVALIER E, PLEBANI M, DELANAYE P, et al. Considerations in parathyroid hormone testing[J]. Clin Chem Lab Med, 2015, 53(12):1913-1919.
[20] COOK M R, PITT S C, SCHAEFER S, et al. A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria[J]. Ann Surg, 2010, 251(6):1127-1130.
[21] 张进军, 夏文飞, 沈文状, 等. 免疫胶体金法甲状旁腺快速鉴定技术及其临床应用价值研究[J]. 中国实用外科杂志, 2018, 38(2):227-230,237.
  ZHANG J J, XIA W F, SHEN W Z, et al. Clinical value of parathyroid hormone-immune colloidal gold technique in intraoperative rapid identification of parathyroid gland[J]. Chin J Pract Surg, 2018, 38(2):227-230,237.
[22] DUDLEY N E. Methylene blue for rapid identification of the parathyroids[J]. Br Med J, 1971, 3(5776):680-681.
[23] WANG L, YANG D, LV J Y, et al. Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: a systematic review and meta-analysis[J]. Onco Targets Ther, 2017, 10:1247-1260.
[24] 潘新民, 严霞, 杨屹立, 等. 甲状腺外科手术中甲状旁腺识别技术研究进展[J]. 中国普通外科杂志, 2023, 32(11):1787-1796.
  PAN X M, YAN X, YANG Y L, et al. Research progress on parathyroid gland recognition techniques during thyroid surgery[J]. Chin J Gen Surg, 2023, 32(11):1787-1796.
[25] ALBUQUERQUE R, CARBONARA C, MARTIN R, et al. Parathyroidectomy in patients with chronic kidney disease: impacts of different techniques on the biochemical and clinical evolution of secondary hyperparathyroidism[J]. Surgery, 2018, 163(2):381-387.
[26] ZHAO S, GAN W, XIE W, et al. A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: a retrospective study[J]. Ren Fail, 2022, 44(1):23-29.
[27] KOMABA H, HAMANO T, FUJII N, et al. Parathyroidectomy vs. cinacalcet among patients undergoing hemodialysis[J]. J Clin Endocrinol Metab, 2022, 107(7):2016-2025.
[28] XI Q P, XIE X S, ZHANG L, et al. Impact of different levels of iPTH on all-cause mortality in dialysis patients with secondary hyperparathyroidism after parathyroidectomy[J]. Biomed Res Int, 2017, 2017:6934706.
[29] KOMABA H, NAKAMURA M, FUKAGAWA M. Resurgence of parathyroidectomy: evidence and outcomes[J]. Curr Opin Nephrol Hypertens, 2017, 26(4):243-249.
[30] EVENEPOEL P, J?RGENSEN H S. Parathyroidectomy versus calcimimetic: the lower the PTH the better?[J]. J Clin Endocrinol Metab, 2022, 107(8):e3532-e3533.
[31] SONG Y H, CAI G Y, XIAO Y F, et al. Can we predict who will develop postoperative hyperkalaemia after parathyroidectomy in dialysis patients with secondary hyperparathyroidism?[J]. BMC Nephrol, 2019, 20(1):225.
[32] YANG G, WANG J, SUN J, et al. Perioperative hyperkalemia in hemodialysis patients undergoing parathyroidectomy for renal hyperparathyroidism[J]. Intern Emerg Med, 2019, 14(7):1065-1071.
[33] ZHU X, LI Z, XIA X, et al. Predictors of hyperkalemia after total parathyroidectomy in patients with drug-refractory secondary hyperparathyroidism[J]. Gland Surg, 2022, 11(4):702-709.
[34] BURES C, ULUK Y, BESMENS M, et al. Hyperkalemia following parathyroidectomy in patients with renal hyperparathyroidism-new thresholds for urgent perioperative dialysis[J]. J Clin Med, 2022, 11(2):409.
[35] ZOU Y, ZHANG L, ZHOU H, et al. Risk factors of hyperkalemia after total parathyroidectomy in patients with se-condary hyperparathyroidism[J]. Ren Fail, 2020, 42(1):1029-1031.
[36] JAIN N, REILLY R F. Hungry bone syndrome[J]. Curr Opin Nephrol Hypertens, 2017, 26(4):250-255.
[37] CHENG M, ZHANG Q, WANG M, et al. A new calculation model for calcium requirements after parathyroidectomy in patients with secondary hyperparathyroidism[J]. Clin Exp Otorhinolaryngol, 2023, 16(3):282-289.
[38] WEN P, XU L, ZHAO S, et al. Risk factors for severe hypocalcemia in patients with secondary hyperparathyroidism after total parathyroidectomy[J]. Int J Endocrinol, 2021, 2021:6613659.
[39] LIU J, HUANG Q, YANG M, et al. Risk factors predicting severe hypocalcemia after total parathyroidectomy without autotransplantation in patients with secondary hyperparathyroidism[J]. J Int Med Res, 2020, 48(1):300060519897505.
[40] FERREIRA J L, DE BRITO MARQUES F, FREIRE L, et al. Intensive calcium monitoring improves outcomes on hungry bone syndrome in hyperparathyroidism[J]. Endocr Regul, 2021, 55(1):30-41.
[41] KANG B H, HWANG S Y, KIM J Y, et al. Predicting postoperative total calcium requirements after parathyroidectomy in secondary hyperparathyroidism[J]. Korean J Intern Med, 2015, 30(6):856-864.
[42] GE P, LIU S, SHENG X, et al. Serum parathyroid hormone and alkaline phosphatase as predictors of calcium requirements after total parathyroidectomy for hypocalcemia in secondary hyperparathyroidism[J]. Head Neck, 2018, 40(2):324-329.
[43] AMLING M, GROTE H J, VOGEL M, et al. Three-dimensional analysis of the spine in autopsy cases with renal osteodystrophy[J]. Kidney Int, 1994, 46(3):733-743.
[44] FANG L, WU J, LUO J, et al. Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism[J]. BMC Nephrol, 2018, 19(1):142.
[45] LU K C, MA W Y, YU J C, et al. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism[J]. Clin Endocrinol (Oxf), 2012, 76(5):634-642.
[46] SHARMA J, ITUM D S, MOSS L, et al. Predictors of bone mineral density improvement in patients undergoing parathyroidectomy for primary hyperparathyroidism[J]. World J Surg, 2014, 38(6):1268-1273.
[47] OKADA M, TOMINAGA Y, TOMOSUGI T, et al. Predictors of bone mineral density improvement after parathyroidectomy for secondary hyperparathyroidism: a retrospective single-center analysis[J]. World J Surg, 2021, 45(9):2777-2784.
[48] WANG A Y, TANG T K, YAU Y Y, et al. Impact of parathyroidectomy versus oral cinacalcet on bone mineral density in patients on peritoneal dialysis with advanced secondary hyperparathyroidism: the proceed pilot randomized trial[J]. Am J Kidney Dis, 2024, 83(4):456-466,e1.
[49] PIRES G O, VIEIRA I O, HERNANDES F R, et al. Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism[J]. Bone, 2019, 121:277-283.
[50] LIN R, VUCAK-DZUMHUR M, ELDER G J. Changes to bone mineral density, the trabecular bone score and hip structural analysis following parathyroidectomy: a case report[J]. BMC Nephrol, 2020, 21(1):513.
[51] YAJIMA A, TSUCHIYA K, BURR D B, et al. The importance of biologically active vitamin D for mineralization by osteocytes after parathyroidectomy for renal hyperparathyroidism[J]. JBMR Plus, 2019, 3(11):e10234.
[52] SAESEOW S, VANTANASIRI K, SUVIKAPAKORNKUL R, et al. Parathyroidectomy is associated with slow progression of vascular calcification in maintenance haemodialysis patients: a propensity score-matched case-control study[J]. Nephrology (Carlton), 2022, 27(4):355-362.
[53] CHEN S, SHENG K, SHEN Y, et al. Impact of parathyroidectomy on left ventricular function in end stage renal disease patients[J]. BMC Nephrol, 2020, 21(1):479.
[54] MA T L, CHANG R Y, CHEN H J, et al. Risk of acute coronary syndrome after parathyroidectomy in patients with end-stage renal disease: a population-based cohort study in Taiwan[J]. Nephrology (Carlton), 2018, 23(2):139-147.
[55] JIANG Y, SHEN Z, ZHANG J, et al. Parathyroidectomy increases heart rate variability and leptin levels in patients with stage 5 chronic kidney disease[J]. Am J Nephrol, 2016, 44(3):245-254.
[56] YIN S M, CHOU F F, WU S C, et al. Applying preoperative dipyridamole thallium-201 scintigraphy for preventing cardiac mortality and complications for patients with secondary hyperparathyroidism undergoing parathyroidectomy[J]. Asian J Surg, 2018, 41(3):229-235.
Options
Outlines

/

〈 〉